ENO2 and amyotrophic lateral sclerosis: A longitudinal evaluation of barrier impairment markers (QAlb or other biomarker candidates such as NSE and S100β) throughout the course of ALS, in combination with inflammatory biomarkers, could give insight into the involvement of BBB/BSCB alteration in the pathogenesis of the disease.